| abstract |
(57) Abstract: (modified with) A to D 1 dopamine agonist to a subject a human or vertebrate, dopamine D 2 agonists and adrenergic alpha 1 antagonists, adrenergic alpha 2 A method for modifying or regulating glucose and / or lipid metabolism disorders, which comprises administering in combination with at least one of an agonist and a serotonergic inhibitor, and a therapeutic pharmaceutical composition therefor. Efficacy The combined administration described above improves at least one of the following lipid and glucose metabolism indicators: Body weight, body fat, plasma insulin, plasma glucose and plasma lipids, and plasma lipoproteins. |